Profile
AYTU ZTS TAK HLN TEVA NBIX
Company Name Aytu BioPharma, Inc. Zoetis Inc. Takeda Pharmaceutical Company Limited Haleon plc Teva Pharmaceutical Industries Limited Neurocrine Biosciences, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $16.13M $82.06B $43.45B $42.15B $19.37B $14.77B
Employees 0.15K 14.10K 49.28K 25.41K 35.00K 1.45K
CEO Mr. Joshua R. Disbrow Ms. Kristin C. Peck Mr. Christophe Weber Mr. Brian James McNamara Mr. Richard D. Francis Dr. Kevin C. Gorman Ph.D.
Ratings
AYTU ZTS TAK HLN TEVA NBIX
Quant Rating Score 2 3 2 3 1 3
Quant Rating Sell Neutral Sell Neutral Strong Sell Neutral
Trading
AYTU ZTS TAK HLN TEVA NBIX
Last Close $2.7 $179.84 $13.77 $9.23 $17.1 $146.8
High 52 $3.36 $200.09 $16.32 $9.23 $17.4 $147.46
Low 52 $1.53 $145.54 $12.6 $7.78 $8.12 $101.19
Price vs. 52 Week High -19.64 % -10.12 % -15.63 % 0 % -1.72 % -0.45 %
Price vs. 52 Week Low 76.47 % 23.57 % 9.29 % 18.64 % 110.59 % 45.07 %
Total Return
AYTU ZTS TAK HLN TEVA NBIX
1 Month Return -5.59 % 1.92 % 6.66 % 9.49 % 5.17 % 9.3 %
3 Month Return -7.03 % 13.52 % 5.68 % 9.23 % 23.82 % 7.95 %
6 Month Return -5.26 % -6.1 % -5.68 % 12.97 % 43.58 % 3.27 %
9 Month Return 1.89 % 15.26 % 2.27 % 18.49 % 110.59 % 38.4 %
YTD Return -4.93 % -8.88 % -3.5 % 12.15 % 63.79 % 11.41 %
1 Year Return 63.64 % -4.69 % -11.79 % 6.28 % 103.09 % 44.99 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
AYTU ZTS TAK HLN TEVA NBIX
Dividend Yield Percentage (TTM) - 0.93 % 4.08 % 2.12 % - -
Dividend Paid and Capex Coverage Ration (TTM) - 1.76 % 0.92 % - 3.3 % 20.82 %
Dividend Per Share (TTM) - 1.67 % 0.56 % 0.15 % - -
Payout Ratio (TTM) - 29.95 % 199.34 % - - -
Growth
AYTU ZTS TAK HLN TEVA NBIX
Asset Growth -0.84 % -4.28 % 8.25 % -2.18 % -1.2 % 37.27 %
Gross Profit Growth 27.44 % 3.7 % -16.6 % 5.85 % 9.64 % 26.06 %
Revenue Growth 11.1 % 5.74 % 5.87 % 4.09 % 6.16 % 26.76 %
Revenue 3 Year -73.7 % 31.98 % 33.13 % 13.9 % -6.92 % 71.93 %
Revenue 5 Year -97.08 % 53.64 % 149.89 % 32.87 % -23.33 % 308.36 %
Revenue 10 Year -85.3 % 103.1 % 154.38 % 32.87 % -40.82 % 44100.16 %
EBIT Growth -145.86 % 6.27 % 7.34 % 37.26 % -84.52 % 0.76 %
Net Income Growth 84.52 % 10.88 % -54.56 % -1.04 % 76.24 % 61.62 %
Net Income 3 Yeari Growth Per Share 68.82 % 47.55 % -61.74 % -8.67 % 86.29 % -41.58 %
Net Income 5 Yeari Growth Per Share 99.83 % 71.94 % 62.27 % 59.66 % 76.28 % 1054.95 %
Net Income 10 Yeari Growth Per Share 99.93 % 404.24 % 36.33 % 59.66 % -133.42 % 470.4 %
Operating Income Growth -145.86 % 6.27 % 7.34 % 37.26 % -84.52 % 0.76 %
Operating Cash Flow Growth (CFG) 82.21 % 23.06 % -34.47 % -16.48 % -13.96 % 14.88 %
Operating 3 Year CFG 98.78 % 14.12 % -36.76 % 22.08 % 10.09 % 62.6 %
Operating 5 Year CFG 99.97 % 37.69 % 139.61 % 118.54 % -48.98 % 275.6 %
Operating 10 Year CFG 99.97 % 274.61 % 335.67 % 118.54 % -67.94 % 1000.37 %
EPS Growth 93.18 % 12.64 % -54.92 % - 76.42 % 59.01 %
EPS Diluted Growth 93.18 % 12.92 % -54.86 % - 76.42 % 58.33 %
Book Value Per Share -62.42 % 15.34 % 13.54 % 1.38 % -5.72 % 28.15 %
Share Holder 3 Year Equity Growth Per Share -97.2 % 36.7 % 40.38 % -36.6 % -26.74 % 88.86 %
Share Holder 5 Year Equity Growth Per Share -99.71 % 139.55 % 73.27 % -39.41 % -53.44 % 353.33 %
Share Holder 10 Year Equity Growth Per Share 100.09 % 476.36 % 197.1 % -39.41 % -74.76 % 1167.34 %
Dividend Per Share Growth - 15.15 % 1.95 % -85.58 % - -
Dividend 3 Year Growth Per Share - 87.76 % 1.19 % -83.69 % - -
Dividend 5 Year Growth Per Share - 198.29 % - -66.42 % -100 % -
Dividend 10 Year Growth Per Share - 665.58 % 103.93 % -66.42 % -100 % -
Debt Growth -10.05 % -15.91 % 24.67 % -9.43 % -6.53 % 62.95 %
Free Cash Flow Growth 82.21 % 22.25 % -53.54 % -20.06 % -19.19 % 11.99 %
Updated On 30 Jun 2023 31 Dec 2023 31 Mar 2024 31 Dec 2023 31 Dec 2023 31 Dec 2023
Profitability
AYTU ZTS TAK HLN TEVA NBIX
Gross Profit Margin TTM 65.32 % 69.2 % 66.54 % 60.04 % 48.99 % 97.78 %
Return on Assets TTM -10.62 % 16.66 % 0.95 % - -1.15 % 10.65 %
Return on Equity TTM -40.5 % 48.41 % 2.06 % 6.53 % -6.86 % 17.45 %
Return on Capital Employed TTM -3.18 % 25.86 % 3.22 % - 3.75 % 17.05 %
Net Income Per EBT TTM 108.51 % 80.07 % 293.72 % 64.62 % 59.18 % 78.68 %
EBT Per Ebit TTM 878.82 % 92.82 % 11.92 % 82.52 % -76.63 % 99.89 %
EBIT Per Revenue TTM -1.53 % 36.83 % 9.65 % 18.08 % 6.79 % 23.73 %
Cash Flow To Debt Ratio TTM 28.4 % 36.43 % 14.47 % - 8.57 % 118.01 %
Receivables Turnover TTM 3.13 6.75 6.11 - 4.63 4.4
Payables Turnover TTM 3.1 6.64 4.46 - 3.35 0.5
Inventory Turnover TTM 2.46 1.01 1.18 - 2.07 1.18
Fixed Asset Turnover TTM 3394.57 % 251.27 % 214.28 % - 267.75 % 572.67 %
Asset Turnover TTM 72.76 % 60.87 % 28.22 % - 37.45 % 57.08 %
Operating Cash Flow Per Share TTM 1.58 5.24 452.66 - 1.5 6.47
Free Cash Flow Per Share TTM 1.58 3.82 146.27 - 1.04 6.16
Cash Per Share TTM 357.09 % 431.22 % 29177.57 % 22.71 % 266.34 % 1213.03 %
Operating Cash Flow Sales Ratio TTM 9.35 % 27.47 % 16.66 % - 10.51 % 32.56 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 72.95 % 32.31 % - 69.66 % 95.2 %
Cash Flow Coverage Ratios TTM 28.4 % 36.43 % 14.47 % - 8.57 % 118.01 %
Price To Free Cash Flows Ratio TTM 1.84 46.89 29.1 - 16.51 24.05
Price To Operating Cash Flows Ratio TTM 1.7 34.33 4.68 - 11.4 22.7
Price Cash Flow Ratio TTM 1.7 34.33 4.68 - 11.4 22.7
Income Statement (TTM)
AYTU ZTS TAK HLN TEVA NBIX
Revenue $0.11B $8.54B $4263.76B $11.3B $15.85B $1.89B
Gross Profit $0.07B $5.83B $2321.31B $6.96B $7.65B $1.85B
Gross Profit Ratio 62.04% 68.28% 54.44% 61.6% 48.25% 97.9%
EBITDA $-0.01B $3.56B $1254.52B $2.81B $4.27B $0.42B
Net Income $-0.02B $2.34B $144.07B $1.05B $-0.56B $0.25B
EPS Diluted -5.11 5.07 91.16 0.11 -0.5 2.47
Balance Sheet (MRQ)
AYTU ZTS TAK HLN TEVA NBIX
Long Term Debt $0.01B $6.56B $4476.5B $8.8B $18.48B $0.26B
Total Liabilities $0.1B $9.3B $7834.79B $17.33B $35.35B $1.02B
Total Equity $0.04B $4.99B $7274.01B $16.73B $8.13B $2.23B
Total Investments $-0B $0.02B $683.22B $0.07B $0.01B $0.94B
Total Debt $0.02B $6.8B $5463.39B $9.46B $20.15B $0.43B
Total Assets $0.14B $14.29B $15108.79B $34.06B $43.48B $3.25B
Cash Flow Statement (TTM)
AYTU ZTS TAK HLN TEVA NBIX
Net Income $-0.02B $2.34B $144.07B $1.05B $-0.62B $0.25B
Inventory $-0B $-0.36B $-115.74B $-0.13B $-0.15B $0.01B
Dividends Paid $0B $-0.69B $-287.19B $-0.39B $0B $0B
Operating Cash Flow $-0.01B $2.35B $640.32B $1.72B $1.37B $0.39B
Capital Expenditure $0B $-0.73B $-480.73B $-0.34B $-0.53B $-0.03B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 5.9
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.45
AKAN Akanda Corp. 1.63
ALIM Alimera Sciences, Inc. 5.57
ALVO Alvotech 11.59
ALVOW Alvotech 2.59
AMPH Amphastar Pharmaceuticals, Inc. 42.48
AMRX Amneal Pharmaceuticals, Inc. 7.44
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 63.25
AQST Aquestive Therapeutics, Inc. 3.82
ASRT Assertio Holdings, Inc. 1.505
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 16.72
BDSI BioDelivery Sciences International, Inc. 5.59
ETFs With Exposure to AYTU
Ticker ETF Name Weight Percentage Price
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.00001 119.77
VXF Vanguard Extended Market Index Fund 0 178.79
PQSV PGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Value ETF 0.1 66.2468
DFAT Dimensional U.S. Targeted Value ETF 0.00009002 56.79
DFAC Dimensional U.S. Core Equity 2 ETF 0.00000849 33.02
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0 135.6
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0 135.6
JKK iShares Morningstar Small-Cap Growth ETF 0 307.42
JKL iShares Morningstar Small-Cap Value ETF 0 172.726
VEMPX Vanguard Extended Market Index InstlPlus 0 334.63
Unlock